search
Back to results

: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Primary Purpose

Advanced Solid Tumor

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
Fruquintinib in Combination with Sintilimab
Sponsored by
Hutchmed
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Advanced Solid Tumor focused on measuring Fruquintinib, Sintilimab, VEGFR, PD-1, Solid Tumor

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Signed informed consent;
  2. 18-75 years old; BMI≥18.5;
  3. Dose-escalation Phase: Histological or cytological diagnosed unresectable or metastatic advanced solid tumor (including hepatic cell cancer, ovarian cancer, endometrial cancer, thymic cancer, NSCLC and renal cancer); Expansion Phase: Histological or cytological diagnosed unresectable or metastatic advanced hepatic cell cancer, renal cancer, endometrial cancer, gastrointestinal tumor;
  4. Subjects in expansion phase need to provide tissue specimen for the test of MSI or dMMR;
  5. Requirements for previous anti-tumor system therapy:

    • Dose escalation stage: patients who have failed standard treatment (disease progression after treatment or intolerable side effects of treatment), no standard treatment method or unable to receive standard treatment
    • Patients enrolled in the study expansion phase are required to receive a standard treatment after disease progression, or toxicity is intolerable, or unable to receive standard treatment. The standard treatment requirements for patients with hepatocellular carcinoma, renal cell carcinoma, endometrial cancer and gastrointestinal tumors (gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and colorectal adenocarcinoma) are as follows:

      • Patients with hepatocellular carcinoma have received a molecular targeted therapy (sorafenib or lenvatinib) or/and systemic chemotherapy (arsenite monotherapy or oxaliplatin-based combination drugs);
      • Patients with renal cell carcinoma have received a standard systemic anti-tumor treatment (sunitinib, sorafenib, pezopanib, axitinib, carbotinib, bevacizumab combined with IFN-α , Temsirolimus, interleukin-2 or IFN-α);
      • Patients with endometrial cancer have received a systemic anti-tumor therapy (except hormone therapy);
      • Patients with gastric adenocarcinoma and gastroesophageal junction adenocarcinoma have previously failed standard chemotherapy;
      • Patients with colorectal adenocarcinoma have previously received fluorouracil + leucovorin + platinum or irinotecan ± cetuximab or bevacizumab combination therapy.
  6. ECOG (Eastern Cooperative Oncology Group) performance status of 0-1;
  7. Child-Pugh score of A (< 7) for hepatic cell cancer;
  8. Measurable lesions per the response evaluation criteria (RECIST 1.1) ,patients with gastric cancer require measurable lesions outside the stomach (Patients with only evaluable lesions are eligible for dose escalation stage); If the patient had regional therapy on the only lesion she/he has, it must have imaging evidence confirming disease progression after the regional therapy;
  9. The test value for bone marrow, liver and renal function evaluation within 7 days prior to first dosing should meet the requirements below:

    • absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelet count ≥ 100 x 109/L(platelet of HCC patients ≥ 80 × 109 / L ) and hemoglobin ≥ 9.0 g/dL;
    • TBIL ≤ 1.5 × ULN;
    • ALT and/or AST ≤ 1.5 × ULN, or ≤ 3 × ULN for subjects with liver metastasis/ hepatic cell cancer;
    • Albumin ≥ 28g/L;
    • Creatinine ≤ 1.5 × ULN or creatinine clearance ≥50 mL/min;
    • Proteinuria <2+ by urinalysis; if Proteinuria ≥2+, proteinuria #1g by 24-hours urinary protein test is required;
    • INR ≤ 1.5 and APTT ≤ 1.5 × ULN;
  10. Life expectancy of more than 12 weeks;
  11. Negative of blood pregnancy test within 7 days prior to first dosing for fertile female patients. Fertile female and male patients agree to use effective contraceptive methods during the study and within 6 months post to the last dose, such as double barrier contraception, condoms, oral or injection contraceptives, intrauterine devices, abstinence, etc. All female patients will be considered fertile unless the female patient has natural menopause or has undergone artificial menopause or sterilization (hysterectomy, bilateral appendage resection);

Exclusion Criteria:

  1. The adverse events due to previous anti-tumor therapy has not recovered to ≤ CTCAE Grade 1, except alopecia and peripheral neurotoxicity with ≤ CTCAE grade 2 caused by platinum chemotherapy;
  2. Suffering with other malignant tumors within 5 years prior to screening (expect cured basal cell carcinoma or squamous carcinoma at skin, cervical carcinoma in situ) only for patients at dose expansion stage;
  3. Fibrolamellar hepatocellular carcinoma or sarcomatoid hepatocellular carcinoma or a component of the above pathological types (HCC),or gastric squamous cell carcinoma or gastric adenosquamous carcinoma confirmed by histology diagnosis
  4. Central nervous system (CNS) metastasis in previous or screening;
  5. Systematic anti-tumor therapy with approved or investigational drugs within 4 weeks prior to first dosing, including but not limited to: chemotherapy (A 2-week wash-out period required for oral fluorouracil), endocrine therapy, and bio-immunotherapy, targeted therapy (A 2-week or 5-half-lives washout period for small molecule target therapy) and traditional Chinese medicine (limited to the traditional Chinese medicine with clear indication for anti-tumor; a 1-week wash-out period required prior to first dosing);
  6. Radical radiotherapy (more than 25% bone marrow involved) within 4 weeks prior to first dosing;
  7. Brachytherapy (such as radioactive beads implantation) within 60 days prior to first dosing;
  8. Any therapy with anti-PD-1, or anti-PD-L1/l2 antibodies or anti-cytotoxic T lymphocyte associated antigen-4 (CTLA-4) antibody (or any other antibody acting on T cell costimulatory or checkpoint pathway) or fruquintinib treatment in previous;
  9. Steroids (more than 10 mg/day prednisone or other equivalent hormones) or other immunosuppressive agents for systemic therapy within 4 weeks prior to first dosing, except nasal spray, inhaled or other topical use of steroid (i.e. no more than 10mg/day prednisone or equivalent doses of other corticosteroids);
  10. History of any active autoimmune disease or autoimmune disease, including but not limited to interstitial pneumonia, uveitis, inflammatory bowel disease, hepatitis, pituitary inflammation, vasculitis, systemic lupus erythematosus, etc. (except patients with hypothyroidism that can be controlled only by hormone replacement therapy and patients with type I diabetes who only need insulin replacement therapy);
  11. Any live or attenuated live vaccine within 4 weeks prior to first dosing or planned for the duration of the study;
  12. Major surgeries within 60 days prior to first dosing;
  13. Any surgery or invasive treatment (except puncture biopsy, intravenous catheterization), or unhealed wounds, ulcers, fractures within 4 weeks prior to first dosing;
  14. Uncontrollable malignant pleural effusion, ascites or pericardial effusion (defined as ineffectively controlled by diuresis or puncture drainage judged by investigators);
  15. Drug uncontrollable hypertension, defined as systolic blood pressure ≥ 140 mmHg and / or diastolic blood pressure ≥ 90 mmHg;
  16. Any disease or condition affecting drug absorption, or inability to take the investigational drug orally;
  17. CYP3A4 inducers or inhibitors, P-gp or BCRP (Breast Cancer Resistant Protein) substrates were taken within 2 weeks or less than 5 half-lives (whichever was longer) prior to first dosing
  18. The patients have active ulcer of stomach and duodenum, ulcerative colitis and other digestive tract diseases or unresectable tumors with active bleeding, or other conditions that may cause gastrointestinal bleeding and perforation, as judged by investigators; or the existence of gastrointestinal perforation or gastrointestinal fistula uncured post to previous surgical treatment;
  19. Patients with evidence or history of propensity to hemorrhage within 2 months prior to first dosing, regardless of severity(such as melena, hematemesis, hemoptysis, bloody stools);
  20. High risk of bleeding at screening due to tumor invasion into major vessels, such as pulmonary artery, the superior vena cava, or the inferior vena cava, as determined by investigators;
  21. Arterial thrombosis or deep venous thrombosis within 6 months prior to first dosing, or thromboembolic events (including stroke and/or transient ischemic attack) within 12 months prior to first dosing;or due to implanted venous infusion pump or catheter-derived thrombosis ,or those with superficial venous thrombosis;
  22. Cardiovascular diseases of significant clinical significance, including, but not limited to acute myocardial infarction, severe/unstable angina pectoris or coronary artery bypass grafting within 6 months prior to first dosing, congestive heart failure with New York Heart Association (NYHA) grade ≥ 2; Left ventricular ejection fraction (LVEF) < 50%;
  23. Clinically significant abnormal electrolyte abnormality as judged by investigators;
  24. Active infection or fever of unknown origin prior to first dosing (body temperature > 38.5 oC) at screening;
  25. Patients with active pulmonary tuberculosis receiving anti-tuberculosis treatment or with anti-tuberculosis treatment within 1 year prior to first dosing;
  26. History of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, severe impairment of the lung function, etc., which may interfere with the detection and treatment of suspected drug-related lung toxicity, except radiation pneumonitis in the radiation treatment area;
  27. Confirmed human immunodeficiency virus (HIV) infection;
  28. Clinically significant liver disease, including active viral hepatitis [HBsAg and/or HbcAb is positive and HBV (hepatitis B virus) DNA > 10000 copies/ mL or > 2000 IU/mL; HCV (hepatitis C virus) antibody positive and HCV RNA positive], or other active hepatitis, clinically significant moderate to severe cirrhosis;
  29. Any unapproved drug taken within 4 weeks prior to first dosing.
  30. Female patients with pregnancy or breastfeeding;
  31. History of allergies to any ingredient of Sintilimab or Fruquintinib or significant allergy history to any mono-antibody;
  32. Any condition by which investigators judge patients not suitable to participate in this study

Sites / Locations

  • Shanghai East HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

VEGFR cohort:

Arm Description

Fruquintinib

Outcomes

Primary Outcome Measures

Safety outcome evaluation - Dose Limited Toxicity (DLT), Maximum Tolerated Dose (MTD).
Safety in the first 28-Day of Study Treatment. Observe the possibly occurs Dose Limited Toxicity (DLT), Maximum Tolerated Dose (MTD), to confirm the Recommended Phase 2 Dose (RP2D).
Safety outcome evaluation - incidence, severity and outcomes of AEs (Adverse Event)
Safety and tolerance evaluated by incidence, severity and outcomes of AEs
Efficacy outcome evaluation - Objective response rate
Objective response rate (ORR),
Efficacy outcome evaluation - Disease control rate
Disease control rate (DCR),
Efficacy outcome evaluation - Progression free survival
Progression free survival (PFS),
Efficacy outcome evaluation - Overall survival
Overall survival (OS)

Secondary Outcome Measures

Immunogenicity Assessments for Anti-drug Antibody(ADA)
Immunogenicity Assessments for Anti-drug Antibody(ADA)
Pharmacokinetics Assessments for Peak Plasma Concentration (Cmax)
Pharmacokinetics Assessments for Peak Plasma Concentration (Cmax)
Pharmacokinetics Assessments for Minimum Plasma Concentration (Cmin)
Pharmacokinetics Assessments for Minimum Plasma Concentration (Cmin)
Pharmacokinetics Assessments for peak time (Tmax)
Pharmacokinetics Assessments for peak time (Tmax)
Pharmacokinetics Assessments for half-life (T1/2)
Pharmacokinetics Assessments for half-life (T1/2)
Pharmacokinetics Assessments for Assessments for Area under the plasma concentration versus time curve (AUC0-t, AUC0-∞)
Pharmacokinetics Assessments for Assessments for Area under the plasma concentration versus time curve (AUC0-t, AUC0-∞)
Pharmacokinetics Assessments for Apparent Clearance (CL/F)
Pharmacokinetics Assessments for Apparent Clearance (CL/F)
Pharmacokinetics Assessments for apparent volume of distribution (Vz/F)
Pharmacokinetics Assessments for apparent volume of distribution (Vz/F)

Full Information

First Posted
March 27, 2019
Last Updated
July 9, 2023
Sponsor
Hutchmed
search

1. Study Identification

Unique Protocol Identification Number
NCT03903705
Brief Title
: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors
Official Title
A Phase Ib/II Study To Evaluate The Safety, Tolerability, Pharmacokinetic Profile And Preliminary Efficacy Of Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 25, 2019 (Actual)
Primary Completion Date
September 2023 (Anticipated)
Study Completion Date
September 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hutchmed

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a phase Ib/II study to evaluate the safety, tolerability, PK profile and preliminary efficacy of fruquintinib monotherapy or plus sintilimab for advanced solid tumors. This study includes fruquintinib plus sintilimab treatment arm (dose escalation phase and dose expansion phase), and fruquintinib monotherapy arm.
Detailed Description
This study is composed of Fruquintinib plus sintilimab treatment arm and Fruquintinib monotherapy arm. Fruquintinib plus sintilimab treatment arm: Dose escalation phase: it is planned to enroll about 26-39 patients Dose expansion phase: it is planned to enroll about 314 patients, including about 129 patients with endometrial cancer Fruquintinib monotherapy arm: about 13 patients with advanced endometrial cancer

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Solid Tumor
Keywords
Fruquintinib, Sintilimab, VEGFR, PD-1, Solid Tumor

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Model Description
Open-Label Phase 1b/II Study of Fruquintinib in Combination with Sintilimab to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced Solid Tumor.
Masking
None (Open Label)
Allocation
N/A
Enrollment
353 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
VEGFR cohort:
Arm Type
Experimental
Arm Description
Fruquintinib
Intervention Type
Drug
Intervention Name(s)
Fruquintinib in Combination with Sintilimab
Intervention Description
Cohort A: Fruquintinib 3 mg QD, oral dosing, 3 weeks on/1 weeks off +Sintilimab 200mg Q4W, intravenous dosing. Cohort B: Fruquintinib 4 mg QD, oral dosing, 3 weeks on/1 weeks off +Sintilimab 200mg Q4W, intravenous dosing Cohort C: Fruquintinib 5 mg QD, oral dosing, 2weeks on/1 weeks off + Sintilimab 200mg Q3W, intravenous dosing Cohort E: Fruquintinib 3 mg QD, continuous, oral dosing, + Sintilimab 200mg Q3W, intravenous dosing Patients will be treated until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria.
Primary Outcome Measure Information:
Title
Safety outcome evaluation - Dose Limited Toxicity (DLT), Maximum Tolerated Dose (MTD).
Description
Safety in the first 28-Day of Study Treatment. Observe the possibly occurs Dose Limited Toxicity (DLT), Maximum Tolerated Dose (MTD), to confirm the Recommended Phase 2 Dose (RP2D).
Time Frame
From Cycle 1 (each cycle is 28 days) Day 1 to Cycle1 (each cycle is 28 days) Day 28
Title
Safety outcome evaluation - incidence, severity and outcomes of AEs (Adverse Event)
Description
Safety and tolerance evaluated by incidence, severity and outcomes of AEs
Time Frame
From first dose to 30 days post the last dose
Title
Efficacy outcome evaluation - Objective response rate
Description
Objective response rate (ORR),
Time Frame
Every 8 weeks since Cycle1 (each cycle is 28 days) Day 1, until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed up to 12 months)
Title
Efficacy outcome evaluation - Disease control rate
Description
Disease control rate (DCR),
Time Frame
Every 8 weeks since Cycle 1(each cycle is 28 days) Day 1, until disease progression or death or new anti-cancer therapy or withdrawal of consent(assessed up to 12 months)
Title
Efficacy outcome evaluation - Progression free survival
Description
Progression free survival (PFS),
Time Frame
From Cycle 1(each cycle is 28 days) Day 1 to disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent(assessed up to 12 months).
Title
Efficacy outcome evaluation - Overall survival
Description
Overall survival (OS)
Time Frame
From Cycle 1(each cycle is 28 days) Day1 to death or loss of follow-up or withdrawal of consent(assessed up to 12 months)
Secondary Outcome Measure Information:
Title
Immunogenicity Assessments for Anti-drug Antibody(ADA)
Description
Immunogenicity Assessments for Anti-drug Antibody(ADA)
Time Frame
From Cycle 1, 2, 4, 6, 8, 12 (each cycle is 28 days) and the safety visit for Sintilimab until disease progression or death or new anti-cancer therapy or withdrawal of consent(assessed up to 12 months)
Title
Pharmacokinetics Assessments for Peak Plasma Concentration (Cmax)
Description
Pharmacokinetics Assessments for Peak Plasma Concentration (Cmax)
Time Frame
From Cycle 1 (each cycle is 28 days) for Fruquintinib and Cycle 1, 2, 3 and 4 for Sintilimab
Title
Pharmacokinetics Assessments for Minimum Plasma Concentration (Cmin)
Description
Pharmacokinetics Assessments for Minimum Plasma Concentration (Cmin)
Time Frame
From Cycle 1 (each cycle is 28 days) for Fruquintinib and Cycle 1, 2, 3 and 4 for Sintilimab
Title
Pharmacokinetics Assessments for peak time (Tmax)
Description
Pharmacokinetics Assessments for peak time (Tmax)
Time Frame
From Cycle 1 (each cycle is 28 days) for Fruquintinib and Cycle 1, 2, 3 and 4 for Sintilimab
Title
Pharmacokinetics Assessments for half-life (T1/2)
Description
Pharmacokinetics Assessments for half-life (T1/2)
Time Frame
From Cycle 1 (each cycle is 28 days) for Fruquintinib and Cycle 1, 2, 3 and 4 for Sintilimab
Title
Pharmacokinetics Assessments for Assessments for Area under the plasma concentration versus time curve (AUC0-t, AUC0-∞)
Description
Pharmacokinetics Assessments for Assessments for Area under the plasma concentration versus time curve (AUC0-t, AUC0-∞)
Time Frame
From Cycle 1 (each cycle is 28 days) for Fruquintinib and Cycle 1, 2, 3 and 4 for Sintilimab
Title
Pharmacokinetics Assessments for Apparent Clearance (CL/F)
Description
Pharmacokinetics Assessments for Apparent Clearance (CL/F)
Time Frame
From Cycle 1 (each cycle is 28 days) for Fruquintinib and Cycle 1, 2, 3 and 4 for Sintilimab
Title
Pharmacokinetics Assessments for apparent volume of distribution (Vz/F)
Description
Pharmacokinetics Assessments for apparent volume of distribution (Vz/F)
Time Frame
From Cycle 1 (each cycle is 28 days) for Fruquintinib and Cycle 1, 2, 3 and 4 for Sintilimab

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Have fully understood and voluntarily sign the ICF for this study (the icf must be signed before any trial-specific procedures are performed); Age of 18-75 years (inclusive); BMI ≥18.5 kg/m2; Tumor types: Fruquintinib plus sintilimab treatment arm Dose escalation phase: patients with histologically or cytologically confirmed inoperable or metastatic advanced solid tumors (including but not limited to HCC, ovarian cancer, endometrial cancer, thymic cancer, NSCLC, renal cell carcinoma); Dose expansion phase: histologically or cytologically confirmed inoperable metastatic advanced HCC (Barcelona Clinic Liver Cancer [BCLC] stage B or C), advanced renal cell carcinoma with clear cell component, advanced endometrial cancer, advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma, advanced colorectal adenocarcinoma, advanced NSCLC, advanced cervical cancer, etc.; Fruquintinib monotherapy treatment arm: histologically or cytologically confirmed metastatic advanced endometrial cancer that cannot be surgically resected or treated with radical radiotherapy; In the expansion phase, patients should agree to provide tissue specimens for detection of PD-L1 expression levels and/or MSI or dMMR status; Requirement for prior systemic antitumor therapy: Fruquintinib plus sintilimab treatment arm: Dose escalation phase: patients who have failed standard treatment (PD or intolerable toxicity after treatment), have no available standard treatment or cannot receive standard treatment (such as economic limitations); Dose expansion phase: Part 1 Patients (HCC, renal cell carcinoma, endometrial cancer, gastric adenocarcinoma or gastroesophageal junction adenocarcinoma, colorectal adenocarcinoma, cervical cancer, NSCLC) should have PD or intolerable toxicity after 1 standard treatment, or cannot receive standard treatment (such as economic limitations or patient's wishes, etc.). Among them, requirements of standard treatment are defined as follows: Patients with HCC who have received 1 molecular targeted therapy (sorafenib or lenvatinib) or/and systemic chemotherapy (arsenious acid monotherapy or oxaliplatin-based combination therapy); Patients with renal cell carcinoma who have received 1 standard systemic antitumor therapy (sunitinib, sorafenib, pazopanib, axenia, cabozantinib, bevacizumab plus IFN-α, temsirolimus); Patients with endometrial cancer who have received ≤2 line of platinum-based double drug systemic antitumor therapy (excluding hormonal therapy) and had PD or Grade ≥3 SAE, or had recurrence or PD after completion of at least 4 cycles of platinum-based double drug chemotherapy. Patients with recurrence or metastasis during or within 6 months after completion of neoadjuvant/adjuvant chemotherapy with platinum-based regimen are considered to have received first-line treatment (4 cycles are required for neoadjuvant/adjuvant chemotherapy, and if less than 4 cycles, it is also eligible to have PD or Grade ≥3 SAE during the treatment); Patients with cervical cancers who have recurrent or metastasized squamous cell carcinoma, adenocarcinoma, or adeno-squamous carcinoma after at least one line of platinum-based chemotherapy (patients are considered to have received first-line treatment if they have recurrented or metastasized during or within 6 months after platinum-based neoadjuvant or adjuvant chemotherapy); Patients with gastric adenocarcinoma and gastroesophageal junction adenocarcinoma who have failed prior standard chemotherapy and can provide tumor tissues for PD-L1 expression detection with CPS ≥1; Patients with colorectal adenocarcinoma previously treated with fluoropyrimidine+leucovorin calcium+platinum or irinotecan+cetuximab/bevacizumab. Advanced NSCLC (stage IV NSCLC diagnosed per AJCC 8th version): Patients with negative driver gene (EGFR/ALK/ROS-1 negative) who have failed prior standard treatment or have intolerable toxicity, or cannot receive or are unwilling to receive current standard treatment, and with PD-L1 expression level TPS (tumor proportion score) ≥1% tested by central laboratory arranged by the sponsor; Patients with NSCLC diagnosed with squamous cell carcinoma do not require test of EGFR mutation, ALK and ROS1 fusion per current diagnosis and treatment guidelines. Other non-squamous NSCLC patients can be included if they have a prior test report demonstrating no driver gene mutation/rearrangement (EGFR, ALK, ROS1); if there is no prior corresponding gene report, archived or fresh tissue needs to be collected for testing at the study site, or at the central laboratory arranged by sponsor; Patients who have recurrence or metastasis during or within 6 months after prior neoadjuvant/adjuvant therapy are considered as having received first-line therapy. Part 2 To enroll patients with renal cell carcinoma who have not received systemic therapy, the specific requirements are as follows: Patients with renal cell carcinoma have not received any prior systemic antitumor therapy for renal cell carcinoma (patients with recurrence or PD >6 months after postoperative adjuvant chemotherapy can be enrolled), and patients with prior cytokine therapy are allowed. Fruquintinib monotherapy arm: patients with histologically or cytologically confirmed advanced recurrent or metastatic endometrial cancer who cannot be surgically resected or treated with radical radiotherapy and have failed at least 1 standard treatment (including PD and intolerable toxicity). ECOG performance status (ECOG PS) of 0 or 1; Child-Pugh Class A (<7 points) for liver function, only applicable to patients with HCC; Measurable tumor lesions per RECIST 1.1, where patients with gastric tumor are required to have measurable lesions outside of the stomach (in the dose escalation phase, patients with only the evaluable lesions are acceptable); if the lesion priorly treated with local therapy (radiotherapy, ablation, interventional therapy, etc.) is the only lesion, there must be definite imaging evidence of PD for that lesion; Laboratory test results of bone marrow, liver and kidney function, and coagulation function within 7 days before the first dose should meet the following criteria (no blood transfusion, blood products, granulocyte colony-stimulating factor or other hematopoietic stimulating factor correction within 7 days before the laboratory test) Absolute neutrophil count (ANC) ≥1.5×109/L and platelets ≥100×109/L (platelets ≥80×109/L in patients with HCC) and hemoglobin ≥90 g/L; Serum total bilirubin (TBIL) ≤1.5 times upper limit of normal (×ULN); Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≤1.5×ULN without liver metastases; ALT and/or AST ≤3×ULN with liver metastases and HCC; Serum albumin ≥28 g/L; Serum creatinine ≤1.5×ULN or creatinine clearance ≥50 mL/min (calculated per Cockcroft-Gault formula); Protein urine < 2+; if protein urine ≥ 2+, 24-hour protein urine quantification should be <1 g; International normalized ratio (INR) ≤1.5 and activated partial thromboplastin time (APTT) ≤1.5×ULN (except for prophylactic use of anticoagulant drugs); Life expectancy of ≥12 weeks; Female of childbearing potential must have a negative blood pregnancy test within 7 days before the first dose. Male or female patients of childbearing potential should voluntarily use an effective contraceptive method during the study and within 6 months after the last dose of study drug, such as double-barrier contraceptive method, condom, oral or injectable contraceptives, intrauterine device, abstinence, etc. All female patients are considered to be of childbearing potential unless they are postmenopausal, have undergone artificial menopause, or are sterilized (hysterectomy, excision of both adnexa). Exclusion Criteria: The AEs related to prior antitumor therapy which do not recover to ≤ CTCAE Grade 1 before the first dose, except alopecia and peripheral neurotoxicity of CTCAE Grade ≤2 caused by platinum chemotherapy; Patients with other malignant tumors (except cured cutaneous basal cell carcinoma or squamous cell carcinoma, cervical carcinoma in situ) within 5 years before screening, only applicable to patients in expansion phase; Histological diagnosed fibrolamellar HCC, sarcomatoid HCC or mixed components of the above pathological types; or gastric squamous cell carcinoma or gastric adenosquamous carcinoma; or carcinosarcoma or sarcoma (endometrial cancer); Patients with meningeal metastasis or active central nervous system (CNS) metastasis during screen period (for patients with brain metastasis who have prior treatment, if there is no evidence of radiographic progression within ≥4 weeks before the first dose of study drug, and are clinically stable for ≥2 weeks after treatment, and have discontinued corticosteroids within 3 days before the first dose, the patient could be enrolled; for patients with untreated, asymptomatic brain metastasis [i.e., no neurological symptoms, no need for corticosteroid or antiepileptic treatment, no brain metastasis >1.5 cm in long diameter, no significant edema around brain metastasis], they could be enrolled); Systemic antitumor therapy approved or under study within 4 weeks before the first dose, including but not limited to: chemotherapy (oral fluoropyrimidines washout period of 2 weeks), endocrine therapy, biological immunotherapy, targeted therapy (small molecule targeted therapy washout period of 2 weeks or 5 half-lives, whichever shorter), Traditional Chinese Medicine treatment (Traditional Chinese Medicine treatment with definite antitumor indications in the instructions, a 1-week washout period before the first dose is acceptable); Radical radiotherapy (including more than 25% bone marrow radiotherapy) within 4 weeks before the first dose; Brachytherapy (such as implantation of radioactive particles) within 60 days before the first dose; Patients previously treated with any anti-programmed cell death receptor 1 (PD-1) antibody, anti-PD-L1 antibody, anti-PD-L2 antibody or anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody (or any other antibody acting on T cell costimulation or checkpoint pathway) (only for the fruquintinib plus sintilimab treatment arm), or fruquintinib; Corticosteroids (dose >10 mg/day prednisone or equivalent of other corticosteroids) or other immunosuppressive drugs for systemic treatment within 4 weeks before the first dose; nasal spray, inhalation or other topical use of corticosteroids (i.e., no more than 10 mg/day prednisone or equivalent of other glucocorticoids) are allowed; Patients with any active autoimmune disease requiring systemic treatment (i.e., use of disease remission drugs, glucocorticoids or immunosuppressive drugs) within the past 2 years; patients who only need replacement therapy (thyroid, adrenal or pituitary dysfuntion with thyroid, insulin or physiological glucocorticoid replacement therapy) can be enrolled; Any live or attenuated live vaccines within 4 weeks before the first dose or planned administration during the study; Major surgical operation within 60 days before the first dose; Any surgery or invasive treatment within 4 weeks before the first dose (stable fistula formation required for fistulization for 4 weeks, except needle biopsy, venous fistula); or unhealed wounds, ulcers, fractures; Uncontrolled malignant pleural effusion, ascites or pericardial effusion (defined as not effectively controlled by diuretics or paracentesis, as judged by the investigator); Patients with hypertension uncontrolled by drugs, defined as: systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg; Patients with any disease or condition that affects drug absorption, or the patient could not take the drug orally; Strong cytochrome P450 (CYP) 3A4 inducer/inhibitor, p-glycoprotein (P-gp) substrate and breast cancer resistance protein (BCRP) substrate within 2 weeks or less than 5 half-lives (whichever is longer) before the first dose; Patients with active gastric and duodenal ulcer, ulcerative colitwas and other gastrointestinal diseases or unresected tumor with active bleeding, or other conditions that may cause gastrointestinal bleeding and perforation as judged by the investigator; or patients with prior gastrointestinal perforation or gastrointestinal fistula who had not recovered after surgical treatment; Patients with evidence or history of bleeding tendency (such as melena, hematemesis, hemoptysis, bloody feces, etc.) within 2 months before the first dose, regardless of severity; Tumor invading major vascular structures, such as pulmonary artery, superior/inferior vena cava, etc. found during screening, with greater risk of bleeding judged by the investigator; Patients with a history of arterial thrombosis or deep venous thrombosis within 6 months before the first dose; or patients with stroke events and/or transient ischemic attack within 12 months; except that patients with thrombosis caused by implantable venous infusion pump or catheter, or patients with stable superficial venous thrombosis after conventional anticoagulant therapy; Patients with clinically significant cardiovascular disease, including but not limited to acute myocardial infarction, severe/unstable angina or coronary artery bypass grafting within 6 months before the first dose; congestive heart failure of New York Heart Association (NYHA) class ≥ 2; left ventricular ejection fraction (LVEF) of < 50%; Patients with an active infection or unexplained fever (body temperature >38.5oC) during the screening period or before the first dose; Patients with active pulmonary tuberculosis who are receiving anti-tuberculosis treatment or received anti-tuberculosis treatment within 1 year before the first dose; Patients with prior and current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, severely impaired pulmonary function and other conditions that may interfere with the detection and treatment of suspected drug-related pulmonary toxicity; Known human immunodeficiency virus (HIV) infection; Known history of clinically significant liver disease, including active viral hepatitis, (hepatitis B virus surface antigen [HBsAg] and/or hepatitis B virus core antibody [HbcAb] positive, hepatitis B virus [HBV] DNA >10000 copies/mL or > 2000 IU/mL; hepatitis C virus [HCV] antibody positive and HCV RNA positive), or other active hepatitis, clinically significant moderate to severe cirrhosis; Other clinical drug treatment that has not been approved or marketed in China within 4 weeks before the first dose; Women who are pregnant (positive pregnancy test before dose) or breastfeeding; Known hypersensitivity to any component of the sintilimab, fruquintinib formulation, or prior history of severe allergy to any other monoclonal antibody; Patient with any other condition or laboratory abnormalities that, in the opinion of the investigator, will increase the risk of study participation or interfere with the interpretation of study results, and is not suitable for the clinical study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Panfeng Tan, MD
Phone
+86 21 20671828
Ext
5828
Email
panfengt@hmplglobal.com
First Name & Middle Initial & Last Name or Official Title & Degree
Yan Jiang
Phone
+86 158 022 34907
Email
yanjiang@hutch-med.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jin Li
Organizational Affiliation
Shanghai East Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Shanghai East Hospital
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
201203
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jing Li, Doctor
Phone
+86 13761222111
Email
lijin@csco.org.cn

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

We'll reach out to this number within 24 hrs